After a turbulent half-decade marked by sharp swings between profit and loss, Neimeth International Pharmaceuticals Plc closed 2025 with its strongest earnings recovery in years, resetting the company’s financial narrative and reframing investor expectations around sustainability rather than mere
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
